PDF(Pubmed)
Abstract：
BACKGROUND: Heart failure is a common and severe condition, often complicated by diastolic dysfunction. Current standard therapies such as ACEIs and ARBs have limited efficacy in managing diastolic function. Sacubitril/Valsartan, an emerging therapy, warrants rigorous investigation to elucidate its impact on diastolic function in heart failure patients.
METHODS: This systematic review and meta-analysis were conducted adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and utilized the PICO schema. Searches were performed on 4 databases-PubMed, Embase, Web of Science, and Cochrane Library-without temporal restrictions. Inclusion and exclusion criteria were strictly defined, and quality assessments were conducted using the Cochrane Collaboration Risk of Bias tool. Both fixed-effects and random-effects models were used for statistical analysis, depending on inter-study heterogeneity assessed by I2 statistics and Chi-square tests.
RESULTS: Out of 1129 identified publications, 8 studies met the criteria and were included in the meta-analysis. These studies consisted of both randomized controlled trials and cohort studies and featured diverse global populations. Significant reductions were found in the echocardiographic parameter E/e\' ratio and LAVi upon treatment with Sacubitril/Valsartan compared to standard therapies, with mean differences of -1.38 and -4.62, respectively, both with P values < .01.
CONCLUSIONS: This meta-analysis demonstrates that Sacubitril/Valsartan significantly improves diastolic function parameters in heart failure patients compared to standard treatments. These findings underscore the potential benefits of Sacubitril/Valsartan in the management of heart failure, particularly for patients with diastolic dysfunction.
METHODS: This systematic review and meta-analysis were conducted adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and utilized the PICO schema. Searches were performed on 4 databases-PubMed, Embase, Web of Science, and Cochrane Library-without temporal restrictions. Inclusion and exclusion criteria were strictly defined, and quality assessments were conducted using the Cochrane Collaboration Risk of Bias tool. Both fixed-effects and random-effects models were used for statistical analysis, depending on inter-study heterogeneity assessed by I2 statistics and Chi-square tests.
RESULTS: Out of 1129 identified publications, 8 studies met the criteria and were included in the meta-analysis. These studies consisted of both randomized controlled trials and cohort studies and featured diverse global populations. Significant reductions were found in the echocardiographic parameter E/e\' ratio and LAVi upon treatment with Sacubitril/Valsartan compared to standard therapies, with mean differences of -1.38 and -4.62, respectively, both with P values < .01.
CONCLUSIONS: This meta-analysis demonstrates that Sacubitril/Valsartan significantly improves diastolic function parameters in heart failure patients compared to standard treatments. These findings underscore the potential benefits of Sacubitril/Valsartan in the management of heart failure, particularly for patients with diastolic dysfunction.
摘要：
背景：心力衰竭是一种常见且严重的疾病，常并发舒张功能障碍。目前的标准疗法如ACEI和ARB在管理舒张功能方面的功效有限。Sacubitril/缬沙坦,一种新兴的疗法，有必要进行严格的研究，以阐明其对心力衰竭患者舒张功能的影响。
方法：本系统综述和荟萃分析遵循系统综述和荟萃分析指南的首选报告项目，并使用PICO模式。在4个数据库上进行了搜索-PubMed，Embase,WebofScience,和Cochrane图书馆-没有时间限制。严格定义了纳入和排除标准，使用Cochrane协作偏差风险工具进行质量评估。使用固定效应和随机效应模型进行统计分析，取决于通过I2统计和卡方检验评估的研究间异质性。
结果：在1129个确定的出版物中，8项研究符合标准，并被纳入荟萃分析。这些研究包括随机对照试验和队列研究，并以不同的全球人群为特征。与标准疗法相比，使用Sacubitril/Valsartan治疗后，超声心动图参数E/e比值和LAVi显著降低。平均差分别为-1.38和-4.62，两者的P值<.01。
结论：这项荟萃分析表明，与标准治疗相比，沙库必曲/缬沙坦可显著改善心力衰竭患者的舒张功能参数。这些发现强调了沙库必曲/缬沙坦在治疗心力衰竭方面的潜在益处。特别是舒张功能不全的患者。
方法：本系统综述和荟萃分析遵循系统综述和荟萃分析指南的首选报告项目，并使用PICO模式。在4个数据库上进行了搜索-PubMed，Embase,WebofScience,和Cochrane图书馆-没有时间限制。严格定义了纳入和排除标准，使用Cochrane协作偏差风险工具进行质量评估。使用固定效应和随机效应模型进行统计分析，取决于通过I2统计和卡方检验评估的研究间异质性。
结果：在1129个确定的出版物中，8项研究符合标准，并被纳入荟萃分析。这些研究包括随机对照试验和队列研究，并以不同的全球人群为特征。与标准疗法相比，使用Sacubitril/Valsartan治疗后，超声心动图参数E/e比值和LAVi显著降低。平均差分别为-1.38和-4.62，两者的P值<.01。
结论：这项荟萃分析表明，与标准治疗相比，沙库必曲/缬沙坦可显著改善心力衰竭患者的舒张功能参数。这些发现强调了沙库必曲/缬沙坦在治疗心力衰竭方面的潜在益处。特别是舒张功能不全的患者。
